1. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7–30.
Google Scholar | Crossref | Medline2. Leslie, KK, Thiel, KW, Goodheart, MJ, et al. Endometrial cancer. Obstet Gynecol Clin North Am 2012; 39: 255–268.
Google Scholar | Crossref | Medline3. Talhouk, A, McAlpine, JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract 2016; 3: 14–14.
Google Scholar | Crossref | Medline4. Wilson, TO, Podratz, KC, Gaffey, TA, et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990; 162: 418–423; discussion 23–26.
Google Scholar | Crossref | Medline | ISI5. Silva, EG, Deavers, MT, Malpica, A. Undifferentiated carcinoma of the endometrium: a review. Pathology 2007; 39: 134–138.
Google Scholar | Crossref | Medline | ISI6. Gadducci, A, Cosio, S, Spirito, N, et al. Clear cell carcinoma of the endometrium: a biological and clinical enigma. Anticancer Res 2010; 30: 1327–1334.
Google Scholar | Medline | ISI7. Jin, C, Hacking, S, Liang, S, et al. PD-L1/PD-1 expression in endometrial clear cell carcinoma: a potential surrogate marker for clinical trials. Int J Surg Pathol 2020; 28: 31–37.
Google Scholar | SAGE Journals8. Pasanen, A, Ahvenainen, T, Pellinen, T, et al. PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups. Am J Surg Pathol 2020; 44: 174–181.
Google Scholar | Crossref | Medline9. Flier, JS, Underhill, LH, Dvorak, HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650–1659.
Google Scholar | Crossref | Medline10. Byun, JS, Gardner, K. Wounds that will not heal: pervasive cellular reprogramming in cancer. Am J Pathol 2013; 182: 1055–1064.
Google Scholar | Crossref | Medline11. Ha, SY, Yeo, S-Y, Xuan, YH, et al. The prognostic significance of cancer-associated fibroblasts in Esophageal squamous cell carcinoma. PLoS One 2014; 9: e99955.
Google Scholar | Crossref12. Kemi, NA, Eskuri, M, Pohjanen, V-M, et al. Histological assessment of stromal maturity as a prognostic factor in surgically treated gastric adenocarcinoma. Histopathology 2019; 75: 882–889.
Google Scholar | Crossref | Medline13. Cao, L, Sun, P-L, He, Y, et al. Desmoplastic reaction and tumor budding in cervical squamous cell carcinoma are prognostic factors for distant metastasis: a retrospective study. Cancer Manag Res 2020; 12: 137–144.
Google Scholar | Crossref | Medline14. Zhai, Q, Fan, J, Lin, Q, et al. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer. PLoS One 2019; 14: e0223325.
Google Scholar | Crossref15. Nearchou, IP, Kajiwara, Y, Mochizuki, S, et al. Novel internationally verified method reports desmoplastic reaction as the most significant prognostic feature for disease-specific survival in stage II colorectal cancer. Am J Surg Pathol 2019; 43: 1239–1248.
Google Scholar | Crossref | Medline16. Hacking, SM. Tumor budding or tumor baloney? Virchows Arch 2021; 479(2): 435–436.
Google Scholar | Crossref | Medline17. Zhai, L, Ladomersky, E, Lenzen, A, et al. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol 2018; 15: 447–457.
Google Scholar | Crossref | Medline18. Ino, K, Yoshida, N, Kajiyama, H, et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555–1561.
Google Scholar | Crossref | Medline | ISI19. Hacking, SM, Chakraborty, B, Nasim, R, et al. A holistic appraisal of stromal differentiation in colorectal cancer: biology, histopathology, computation, and genomics. Pathol Res Pract 2021; 220: 153378.
Google Scholar | Crossref | Medline20. Mills, A, Zadeh, S, Sloan, E, et al. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol 2018; 31: 1282–1290.
Google Scholar | Crossref | Medline21. Liu, J, Liu, Y, Wang, W, et al. Expression of immune checkpoint molecules in endometrial carcinoma. Exp Ther Med 2015; 10: 1947–1952.
Google Scholar | Crossref | Medline22. de Jong, RA, Kema, IP, Boerma, A, et al. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol 2012; 126: 474–480.
Google Scholar | Crossref | Medline23. Ino, K, Yamamoto, E, Shibata, K, et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 2008; 14: 2310–2317.
Google Scholar | Crossref | Medline24. Long, GV, Dummer, R, Hamid, O, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. J Clin Oncol 2018; 36: 108–108.
Google Scholar | Crossref25. Van den Eynde, BJ, van Baren, N, Baurain, J-F. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma? Annu Rev Cancer Biol 2020; 4: 241–256.
Google Scholar | Crossref26. Joehlin-Price, AS, McHugh, KE, Stephens, JA, et al. The microcystic, elongated, and fragmented (MELF) pattern of invasion: a single institution report of 464 consecutive FIGO grade 1 endometrial Endometrioid Adenocarcinomas. Am J Surg Pathol 2017; 41: 49–55.
Google Scholar | Crossref | Medline27. Espinosa, I, Catasus, L, D’Angelo, E, et al. Stromal signatures in endometrioid endometrial carcinomas. Mod Pathol 2014; 27(4): 631–639.
Google Scholar | Crossref | Medline28. Hornyák, L, Dobos, N, Koncz, G, et al. The role of Indoleamine-2,3-Dioxygenase in cancer development, diagnostics and therapy. Front Immunol 2018; 9: 151.
Google Scholar | Crossref | Medline